Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium

  title={Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium},
  author={Chris R. Triggle and Hong Ding},
  journal={Acta Physiologica},
Metformin, a synthetic dimethyl biguanide, has been in clinical use for over 55 years, and today is considered the first‐choice drug for the treatment of type 2 diabetes used by an estimated 125 million people worldwide. Metformin is orally effective, not metabolized, excreted unchanged by the kidney, relatively free of side effects and well tolerated by the majority of patients. Of importance is that the United Kingdom Prospective Diabetes Study 20‐year study of type 2 diabetics, completed in… 

Metformin - a new approach.

The benefits of using metformin in the treatment of various diseases are presented, including diabetes, cancer, and other diseases.

Can Metformin Exert as an Active Drug on Endothelial Dysfunction in Diabetic Subjects?

Aim of this review is to assess metformin’s beneficial effects on endothelial dysfunction in T2DM, which could preempt development of atherosclerosis.

Metformin and Vascular Diseases: A Focused Review on Smooth Muscle Cell Function

The role and molecular mechanisms by which metformin acts through VSMCs to protect CVD are provided, including AS, restenosis, and pulmonary hypertension.

The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3)

Regardless of glycemic improvement, combination therapy of vildagliptin and metformin did not affect endothelial function but may exert favorable effects on adipokine levels and lipid profile in patients with type 2 diabetes without advanced atherosclerosis.

Metformin, Macrophage Dysfunction and Atherosclerosis

Macrophages play an important role in a variety of diseases, and improving macrophage dysfunction may be an important mechanism for metformin to expand its pleiotropic pharmacological profile.

The Effects of Pycnogenol® as Add‐on Drug to Metformin Therapy in Diabetic Rats

Both used agents, PYC and MET, showed improvement of blood glucose levels, vascular reactivity, left ventricular hypertrophy, expression of AMPK, glucose transporter 4 (GLUT4) and calcium/calmodulin‐dependent protein kinase II (CaMKII) in left ventricle of the hearts, however, the combination of these interventions has failed to possess higher efficacy.

Mechanisms of cardiovascular protection of non-insulin antidiabetic medications

The pathophysiological mechanisms underlying the claimed cardiovascular protection of the different glucose-lowering drugs, the available evidence-based data for their protection, the potential adverse effects, and the different phenotypes of patients eligible for a specific treatment are highlighted.



Metformin: an old but still the best treatment for type 2 diabetes

The role of metformin in the treatment of patients with type 2 diabetes is reviewed, its potential role for a variety of insulin resistant and pre-diabetic states, obesity, metabolic abnormalities associated with HIV disease, gestational diabetes, cancer, and neuroprotection are discussed.

Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium

Critically evaluate the data from studies that have investigated the pharmacokinetic properties and the cellular and clinical basis for the oral hypoglycaemic, insulin-sensitising and vascular protective effects of metformin.

Cellular and molecular mechanisms of metformin: an overview.

Emerging new therapeutic areas for metformin will be reviewed together with recent findings from pharmacogenetic studies linking genetic variations to drug response, a promising new step towards personalized medicine in the treatment of T2D.

Metformin—mode of action and clinical implications for diabetes and cancer

The updated understanding of the antigluconeogenic action of met formin in the liver and the implications of the discoveries of metformin targets for the treatment of diabetes mellitus and cancer are discussed.

Clinical Pharmacokinetics of Metformin

The effect of structural variants of OCTs and other cation transporters on the pharmacokinetics of metformin appears small and the subsequent effects on clinical response are limited, however, intersubject differences in the levels of expression of OCT1 and OCT3 in the liver are very large and may contribute more to the variations in the hepatic uptake and clinical effect of metforms.

Cardiovascular impact of drugs used in the treatment of diabetes

A particular focus is provided on metformin as it is the first choice drug for most patients with type 2 diabetes, and the evidence for their cardiovascular benefits and risks is addressed.

Molecular mechanism of action of metformin: old or new insights?

An improvement in understanding of metformin’s molecular targets is likely to enable target-based identification of second-generation drugs with similar properties, a development that has been impossible up to now.

Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action.

The data indicate that OCT1 is important for metformin therapeutic action and that genetic variation in OCT1 may contribute to variation in response to the drug.

Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain.

It is concluded that the drug's pharmacological effects are mediated, at least in part, through a time-dependent, self-limiting inhibition of the respiratory chain that restrains hepatic gluconeogenesis while increasing glucose utilization in peripheral tissues.